Nonalcoholic Fatty Liver Disease (NAFLD)covers three disease conditions, including simple fatty liver(NAFL), steatohepatitis (NASH)and cirrhosis. According to statistics, 30% of adults in modern society have fatty liver, and there is currently no drug approved for the treatment of NAFLD in the world. Patients can only rely on self-improvement of living habits, such as: more exercise, weight loss, alcohol withdrawal, etc. for treatment.

This time, Phison joined forces with National Taiwan University Hospital and the Good Liver Foundation to pay attention to public health, donated NT$1 million to support the research on non-alcoholic fatty liver drugs, which responded to the SDG3: Good Health and Well-Being with practical actions. If the research goes well, it will benefit countless non-alcoholic fatty liver patients, help patients improve liver function, and promote the well-being of people of all ages.